A German Biotech's $6.5 Million Bet on the Next Heart Disease Breakthrough

Jan de Vries · 2026-08-28

A new player just entered the biotech arena with a fresh approach to some of the most stubborn heart conditions out there. Revier Therapeutics, based in Heidelberg, Germany, has officially launched and secured a $6.5 million Seed round. It's a significant vote of confidence in their plan to tackle cardiometabolic diseases—a category that includes heart failure and atherosclerosis—in a whole new way. This isn't just another funding announcement. It's a story about precision. While progress in cardiovascular medicine is real, millions of patients with specific conditions like HFpEF (heart failure with preserved ejection fraction) and ASCVD (atherosclerotic cardiovascular disease) are still waiting for truly targeted options. Revier's founders believe the next wave of medicine has to go deeper, addressing the underlying biology that drives the disease itself. ### The Science Behind the Strategy So, what's their angle? The company is zeroing in on a specific family of enzymes called class IIa histone deacetylases, or HDACs. Think of earlier HDAC treatments as using a sledgehammer—they hit everything, which often led to nasty side effects. Revier's approach is more like a scalpel. Their orally available small molecules are designed to selectively inhibit only the disease-causing activity of these enzymes, while leaving their healthy functions untouched. It's a first-of-its-kind therapeutic strategy for cardiometabolic diseases. As Prof. Johannes Backs, the company's scientific founder, puts it, this precision is key to being both effective and safe. They're starting their clinical pipeline with HFpEF and ASCVD, two areas with massive unmet patient need. ### Why Investors Are Backing This Vision The $6.5 million seed round was led by the KHAN Technology Transfer Fund II. They were joined by High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg. It's a coalition that sees the potential here. Michael Hamacher from KHAN summed up the investor sentiment, highlighting Revier's "differentiated strategy" to unlock the therapeutic promise of HDAC biology. He pointed to the exceptional leadership team and deep scientific expertise as reasons the company could actually reshape the standard of care and provide lasting benefits for patients. ### What's Next for the Capital? With the fresh capital in hand, Revier has a clear roadmap. The money will fuel the preclinical development of their two lead programs: - Their primary focus on heart failure with preserved ejection fraction (HFpEF). - A parallel program for atherosclerotic cardiovascular disease (ASCVD). Beyond the science, they're also building out their operational, scientific, and clinical teams. It's all about advancing these novel therapies from the lab toward the clinic as efficiently as possible. For founders and professionals watching the European startup scene, especially in life sciences, Revier Therapeutics is a name to remember. It's a perfect example of deep scientific innovation attracting serious capital to solve a critical human problem.